MedTrace Logo

Effect of Progesterone on Latent Phase Prolongation in Patients With Preterm Premature Rupture of Membranes

NCT04807543 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 100

Last updated 2021-03-19

No results posted yet for this study

Summary

The aim of the study is to assess the efficacy of 17-hydroxyprogesterone caproate (17P) therapy on the latency period in pregnant women with Preterm premature rupture of membranes.

Conditions

  • Preterm Premature Rupture of Membrane

Interventions

DRUG

17-hydroxyprogesterone caproate

intramuscular injection weekly

DRUG

Castor Oil

intramuscular injection weekly

Sponsors & Collaborators

  • Ain Shams University

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
SUPPORTIVE_CARE
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
20 Years
Max Age
35 Years
Sex
FEMALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2018-01-10
Primary Completion
2020-10-10
Completion
2020-12-10
FDA Drug
Yes

Countries

  • Egypt

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04807543 on ClinicalTrials.gov